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Objective: Vascular injury results in activation of the mitogen-activated protein
kinases—extracellular-signal regulated kinases, c-jun N-terminal kinase, and
p38MAPK—which have been implicated in cell proliferation, migration, and apopto-
sis. The goal of this study was to characterize mitogen-activated protein kinase
activation in arterialized vein grafts.
Methods: Carotid artery bypass using reversed external jugular vein was performed
in 29 dogs. Vein grafts were harvested after 30 minutes and 3, 8, and 24 hours, and
4, 7, 14, and 28 days. Contralateral external jugular vein and external jugular vein
interposition vein-to-vein grafts were used as controls. Vein graft extracts were
analyzed for extracellular-signal regulated kinases, c-jun N-terminal kinase, and
p38MAPK activation. Proliferating cell nuclear antigen expression was investigated
as a parameter of cell proliferation. Apoptosis was assessed by terminal deoxynu-
cleotidyl transferase–mediated 2'-deoxyuridine 5'-triphosphate nick end labeling
staining and intimal hyperplasia by morphometric examination of tissue sections.
Results: Significant intimal hyperplasia was observed at 28 days. Over the time points
studied, vein graft arterialization resulted in bimodal activation of both extracellular-
signal regulated kinase and p38MAPK (30 minutes through 3 hours; 4 days) but did not
induce activation of c-jun N-terminal kinase. Proliferating cell nuclear antigen expres-
sion increased from days 1 through 28, and apoptosis increased between 8 and 24 hours.
Conclusion: Vein graft arterialization induces bimodal activation of extracellular-signal
regulated kinase and p38MAPK; however, in contrast with what is described in arterial
injury, it does not induce c-jun N-terminal kinase activation. These results provide the
first comprehensive characterization of the mitogen-activated protein kinase signaling
pathways activated in vein graft arterialization and identify mitogen-activated protein
kinases as potential mediators of vein graft remodeling and subsequent intimal hyper-
plasia.
Intimal hyperplasia is a major impediment to long-term patency of autolo-gous vein grafts in cardiac and peripheral vascular bypass surgery.1 Al-though vein grafts are the most widely used conduits for coronary arterybypass grafting (CABG), their ultimate success is limited by high rates oflate stenosis and eventual luminal occlusion. Recent reports show 10% ofvein grafts to be thrombosed within 60 days after CABG and only 50% of
grafts to be patent at 10 years.2,3 By 1 year after CABG, intimal hyperplasia is
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found, to some degree, in all grafts.3 Late graft failure has
a significant clinical impact, resulting in recurrent ischemia
and angina, myocardial infarction, limb loss, reoperation,
and even death.2
The development of intimal hyperplasia in the arterial-
ized vein graft is characterized by uncontrolled proliferation
and migration of medial smooth muscle cells into the intima
and massive deposition of interstitial collagen.1,2,4 The re-
sponse to both mechanical injury and shear stress resembles
that observed in injured arteries after balloon angioplasty
and, more generally, recalls key early events in atherogen-
esis.5 However, the signaling pathways that mediate these
changes and ultimately lead to the formation of neointima
remain unclear.6
Cells respond to external stimuli by activation of intra-
cellular signaling pathways, which can be mediated by
membrane receptors.7 When a signal is transmitted to the
nucleus through a cascade of signal transduction molecules,
the mitogen-activated protein kinases (MAPKs) act as the
ultimate mediators of extracellular stimuli between the
cytoplasm and the nucleus.7 Whereas MAPKs can phos-
phorylate cytoplasmic substrates, in the nucleus they
activate transcription of specific genes by modulating a
variety of transcription factors.7 The 3 major subgroups
of the MAPK family are the extracellular signal-regulated
kinases (ERK-1/2), c-jun N-terminal kinases (JNKs), and
p38MAPK. Both the integration of these pathways and
their kinetics of activation determine cellular behavior
and fate.8
Numerous data obtained with cultured vascular endothe-
lial or smooth muscle cells and with injured arteries link
MAPK activation to cell proliferation, migration, and apo-
ptosis.9-11 Both the ERK-1/2 and JNK pathways are acti-
vated with different kinetics in balloon-injured arteries, and
their inhibition results in decreased medial cell proliferation
and intimal hyperplasia.6,12,13 Although vein grafts remain
of central importance in cardiac and peripheral vascular
surgery, the literature on MAPK activation in vein interpo-
sition grafts is limited. In addition, vein graft arterialization
generates distinctly different stimuli from those induced by
arterial injury following balloon angioplasty and/or stent
implantation.5,14,15 In this study, we used a canine model of
carotid artery bypass to characterize MAPK activation in
arterialized vein grafts.
Figure 1. Vein graft arterialization results in intimal hyperplasia. Representative hematoxylin and eosin–stained
contralateral external jugular vein (C) and arterialized vein graft (AVG) at 28 days. White lines identify intimal
hyperplasia. (40, 100.)
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Methods
Operative Procedure
Carotid artery bypass using reversed autologous external jugular
vein (EJV) was performed on 29 purpose-bred adult mongrel dogs
(25 kg). The animals were premedicated with atropine 0.05
mg/kg IV and anesthetized with ketamine 10 mg/kg IV and diaz-
epam 0.5 mg/kg IV. The dogs were ventilated via endotracheal
tube with 100% oxygen and maintained under anesthesia with
1.5% to 2.0% isoflurane in oxygen at 2 L/min.
A midline neck incision was made from the thyroid cartilage to
the sternal notch and the EJV was exposed with a “no-touch”
technique, and side branches were clipped and divided. After
heparinization (100 U/kg), the ipsilateral common carotid artery
was dissected free and the EJV was ligated, excised, and then
flushed (but not distended) with plasmalyte solution. A segment of
the excised vein was removed and labeled “control 1” (C1). The
vein was grafted to the carotid artery with end-to-side vascular
anastomoses, performed with standard vascular surgical tech-
niques and 7-0 polypropylene suture, and the carotid artery was
ligated and divided. The wound was closed in 2 layers.
At the time of death, the dogs were anesthetized as described
above. Carotid artery and interposition vein graft were exposed
through the previous incision. As a control, a segment of contralat-
eral EJV was mobilized and excised. A 5-mm section was fixed in
formaldehyde (3.7%) for subsequent histologic examination, and
the remainder was placed in lysis buffer (see below) and labeled
“control 2” (C2). An arteriotomy was made in the carotid distal to
the vein graft to confirm its patency. After perfusion with plasma-
lyte solution, the arterialized vein graft was excised and a 5-mm
segment from the midportion of the vein graft was fixed in form-
aldehyde (3.7%) for subsequent histologic examination. The re-
mainder was placed in lysis buffer (see below) and labeled “sam-
ple 3” (S3). Animals were killed using a commercially available
euthanasia solution containing pentobarbital.
All vein grafts were patent at time of harvest, and all operations
were performed without a fatality. Vein grafts were harvested at
each of the following time points: 30 minutes; 3, 8, and 24 hours;
and 4, 7, 14, and 28 days (n  3). These times were chosen to
monitor the rapid activation of intracellular signaling, cell prolif-
eration, and programmed death (apoptosis) and the early stages of
development of intimal hyperplasia. When veins were harvested
3 hours after surgery, the animals were maintained under anes-
thesia; all others were allowed to recover.
As further controls, 3 dogs underwent vein-to-vein bypass
using an EJV vein graft to the contralateral EJV, and 2 dogs
underwent artery-to-artery bypass using a carotid artery graft to the
contralateral carotid artery. Harvested femoral vein and artery
were used as controls for the MAPK activation assays.
Figure 2. Vein graft arterialization induces bimodal ERK-1/2 activation. Representative Western blot comparing
ERK-1/2 activation in contralateral external jugular vein (C) and arterialized vein graft (AVG) at the indicated time
points after arterialization. Upper panel: membranes probed with anti-phospho-ERK-1/2 antibody (pERK-1/2); lower
panel: membranes probed with anti-ERK-2 antibody (ERK-2). Densitometric analysis of ERK-1/2 activation in
contralateral external jugular veins (gray bars) and arterialized vein grafts (white bars). Means  SEM of 3
independent experiments are shown. Overall statistical significance is shown. Asterisk denotes significant
difference from the control at each time point (P < .05) via GLM parameter estimates.
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These procedures conformed with the Guide for the Care and
Use of Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication no. 85-23, revised 1996) and
were approved by the Institutional Animal Care and Use Commit-
tee.
Sample Processing
Immediately after excision, samples were harvested and processed
as previously described.15 A segment of each sample was removed
and fixed in 3.7% formaldehyde for hematoxylin and eosin stain-
ing and immunohistochemical analysis.
Western Blotting
Equal amounts of vein extract protein (20-60 g) were electro-
phoresed in sodium dodecyl sulfate/10% polyacrylamide gels and
blotted onto polyvinylidene fluoride (PVDF) membranes (Milli-
pore, Bedford, Mass). The membranes were incubated with anti-
bodies to the active (phosphorylated) forms of either ERK-1/2 or
p38MAPK (Cell Signaling Technology, Beverly, Mass). As a con-
trol for equal loading and transfer, the membranes were stripped
and reprobed with antibodies to the total form of the corresponding
signaling protein (anti-ERK-2, anti-p38MAPK antibodies, Santa
Cruz Biotechnology, Inc, Santa Cruz, Calif). To study activation of
the JNK pathway, we used an in vitro kinase assay that detects
phosphorylation of a glutathione S-transferase (GST)–Jun fusion
protein by means of a pull-down assay in which c-Jun is both the
bait and the substrate for JNK (Cell Signaling Technology). As a
control for equal loading and transfer, the membranes were
stripped and reprobed with anti–total c-Jun antibody (Cell Signal-
ing Technology). The membranes were incubated with horseradish
peroxidase-labeled anti-rabbit immunoglobulin G antibodies (Am-
ersham Pharmacia Biotech, Inc, Piscataway, NJ), and antigen-
antibody complexes were detected by enhanced chemilumines-
cence (Lumilight, Roche, Indianapolis, Ind).
Quantitative analysis of the immunoreactive bands was per-
formed by scanning densitometry with Kodak 1D Image Analysis
software (Kodak, Rochester, NY). The active forms of each pro-
tein were normalized to the total amount of the corresponding
protein, and kinase activity was measured in arterialized vein
grafts compared with contralateral EJVs.
Histologic and Immunohistochemical Analysis
Cross sections (4-6 m) of fixed vein segments were stained with
hematoxylin and eosin for morphologic examination or Van Gie-
son stain to visualize the elastic fibers. For immunodetection of
active MAPKs, paraffin-embedded sections were processed with
the ABC staining kit (Santa Cruz Biotechnology, Inc) using the
anti-active MAPK antibodies described above, except that phos-
pho-p38MAPK monoclonal antibody (Cell Signaling Technology)
was used. Sections were also immunostained for -smooth muscle
actin (-SMA) using a specific monoclonal antibody (Sigma, St
Louis, Mo).
Figure 3. Vein graft arterialization induces bimodal p38MAPK activation. Representative Western blot comparing
p38MAPK activation in contralateral external jugular vein (C) and arterialized vein graft (AVG) at the indicated time
points after arterialization. Upper panel: membranes probed with anti-phospho-p38MAPK antibody (p38); lower
panel: membranes probed with anti-ERK-2 antibody (pp38). Densitometric analysis of p38MAPK activation in
contralateral external jugular veins (gray bars) and arterialized vein grafts (white bars). Means  SEM of 3
independent experiments are shown. Overall statistical significance is shown. Asterisk denotes significant
difference from the control at each time point (P < .05) via GLM parameter estimates.
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Cell Proliferation and Apoptosis
To monitor cell proliferation, expression of proliferating cell nu-
clear antigen (PCNA), a 36-kDa protein that accumulates in the
nucleus of cells committed to overcome the G1 phase of the cell
cycle, was analyzed by Western blotting of vein graft extracts
using monoclonal antibodies to PCNA (LabVision, Fremont,
Calif). Lysates of proliferating endothelial cells were used as a
positive control for PCNA expression. Detection of antigen-anti-
body complexes and scanning densitometry were performed as
described above. For immunohistochemical detection of PCNA,
paraffin-embedded sections of the vein samples were analyzed
with the same antibodies used for Western blotting.
To detect apoptotic cells, cross sections (4-6 m) of paraffin-
embedded vein segments were stained for ladderized DNA using
the terminal deoxynucleotidyl transferase–mediated 2'-deoxyuri-
dine 5'-triphosphate nick end labeling (TUNEL) assay (Oncogene
Research Products, Boston, Mass). The sections were counter-
stained with the nuclear stain Hoechst 33342 and analyzed with a
fluorescence microscope (Zeiss Axioskop 2, Carl Zeiss, Inc,
Thornwood, NY).
Statistical Analysis
The results were analyzed using the SPSS statistical software
package (version 11; Chicago, Ill). Analysis of variance via a
general linear model (GLM) was used to analyze overall differ-
ences of the effects of time and treatment; parameter estimates
were used for comparison between groups at each time point.
Results are expressed as mean standard error of the mean, unless
otherwise stated.
Results
Vein Graft Arterialization Produces Vascular Injury,
Remodeling, and Intimal Hyperplasia
Interposition vein graft bypass of the carotid artery using
reversed EJVs produced a characteristic series of histologic
changes over 28 days. Early signs of endothelial sloughing
were accompanied by lining of the luminal surface with
leukocytes and leukocytic invasion of the vein wall. By 1 to
4 days, the vein grafts became dilated and showed edema
and occasional hemorrhage in the media, and by 1 week,
small areas of intimal hyperplasia could be observed (data
not shown). By 28 days these areas evolved into eccentric
lesions that encroached into the vein graft lumen (Figure 1).
MAPK Pathways Are Activated in a Bimodal Manner
Following Vein Graft Arterialization
Arterialization of reversed EJV grafts resulted in activation
of ERK-1/2 30 minutes after anastomosis, with stronger
Figure 4. Vein graft arterialization does not induce JNK activation. Representative Western blot of in vitro kinase
reaction products comparing JNK activation in contralateral external jugular vein (C) and arterialized vein graft
(AVG) at the indicated time points after arterialization. Upper panel: membranes probed with anti-phospho-jun
antibody (p-jun); lower panel: membranes probed with anti-c-jun antibody (c-jun). Positive control (Pos) was
obtained by lysing Madin-Darby canine kidney (MDCK) cells 10 minutes after irradiation with 20 mJ/cm2 of UV-C.
Densitometric analysis of JNK activation in contralateral external jugular veins (gray bars) and arterialized vein
grafts (white bars). Means  SEM of 3 independent experiments are shown. Overall statistical significance is
shown.
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activation occurring at 3 hours. A second peak of ERK-1/2
activation was observed at 4 days (although not statistically
significant), after which ERK-1/2 activation decreased to-
ward control levels (Figure 2). Vein graft arterialization also
resulted in strong activation of p38MAPK at 30 minutes and
3 hours (Figure 3). A second peak of activation was ob-
served at 4 days.
Preliminary attempts to investigate the JNK pathway by
using phospho-specific antibodies failed to yield consistent
results (data not shown). Therefore, we chose a more sen-
sitive in vitro kinase assay that detects phosphorylation of
c-jun, a specific JNK substrate. Unlike ERK-1/2 and
p38MAPK, vein graft arterialization did not result in consis-
tent JNK activation (Figure 4).
Confirming the Western blotting results, immunohis-
tochemical analysis of arterialized vein grafts showed
active ERK-1/2 and p38MAPK associated with -SMA
positive cells at 30 minutes, 3 hours, and 4 days (Figure
5).
Vein Graft Arterialization Induces Both Medial Cell
Proliferation and Apoptosis
To characterize the effect of vein arterialization on cell
proliferation, we analyzed PCNA expression by Western
blotting. As shown in Figure 6, A, no induction of PCNA
expression was detected at 30 minutes, 3 hours, or 8 hours.
At 24 hours, a modest induction of PCNA expression was
observed in arterialized vein grafts as compared with con-
trols. Subsequently, an 8- to 14-fold increase of PCNA
expression over control levels was detected from 4 days to
28 days. Immunohistochemical analysis confirmed these
findings, with strong staining for PCNA in the inner media
and neointima (Figure 6, B).
Because apoptosis has been shown to occur after vein
graft arterialization in a swine model,16 we investigated
whether programmed cell death also occurs in our model. As
shown in Figure 6, C, TUNEL assay of sections of arterialized
vein grafts and contralateral EJV showed apoptosis in the inner
media at 8 hours and 24 hours after arterialization, whereas
Figure 5. ERK-1/2 and p38MAPK activation occurs in medial and luminal cells after vein graft arterialization.
Immunohistochemical staining of contralateral external jugular vein (C) and arterialized vein graft (AVG) with
anti-phospho-ERK-1/2 antibody and anti-phospho-p38MAPK antibody. (400.)
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apoptosis was barely detected at later time points (data not
shown). Thus, an early onset of apoptosis is accompanied by
and followed by cellular proliferation.
Vein-to-Vein and Artery-to-Artery Bypass Grafting
Does Not Result in MAPK Activation or PCNA
Expression
To test whether the observed MAPK activation was specific
to arterialized vein grafts or a nonspecific effect of vessel
manipulation, EJV grafts were used to bypass the contralateral
EJV. In contrast to vein graft arterialization, vein-to-vein by-
pass grafting did not induce ERK-1/2 or p38MAPK activation
(Figure 7, A). Similarly, carotid arterial grafts used to bypass
the contralateral carotid artery did not show MAPK activation
(Figure 7, A). Similarly, no PCNA induction was detected in
vein-to-vein bypass at 4 days (Figure 7, B).
Discussion
Although the literature on MAPK activation in arterial
injury is extensive, to date a similar activation during vein
Figure 6. Vein graft arterialization induces medial and luminal cell proliferation and apoptosis. A, Representative
Western blot comparing PCNA expression in contralateral external jugular vein (C) and arterialized vein graft
(AVG) at the indicated time points after arterialization. Upper panel: membranes probed with anti-PCNA antibody
(PCNA). Densitometric analysis of PCNA expression in contralateral external jugular veins (gray bars) and
arterialized vein grafts (white bars). Means  SEM of 3 independent experiments are shown. Overall statistical
significance is shown. Asterisk denotes significant difference from the control at each time point (P < .05) via GLM
parameter estimates. B, Immunohistochemical staining of PCNA in arterialized vein graft (AVG) compared with
contralateral external jugular vein (C) at 4 days. C, TUNEL staining shows increased apoptosis in arterialized vein
grafts (AVG) compared with contralateral external jugular veins (C) at 8 and 24 hours. (200.)
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graft arterialization has only been suggested by observations
on mechanical stretching of cultured smooth muscle cells17
or excised vessels.18 Our study therefore represents the first
characterization of MAPK activation following vein graft
arterialization and indicates MAPKs as important intracel-
lular mediators of stimuli produced during vein arterializa-
tion. In addition, our data suggest a molecular mechanism to
explain differences between the type of injury that occurs in
arterialized vein grafts and arterial injury, possibly elucidat-
ing how the stimuli are sensed in the 2 systems. In fact,
similar to arterial injury, vein graft arterialization results in
early activation of ERK-1/2 and p38MAPK, with a second
activation peak observed later at 4 days. Unlike arterial
injury, vein graft arterialization does not cause activation of
JNK.6
Previous studies combining in vivo observations and
analysis of cultured vascular cells have suggested a poten-
tial role for MAPKs in vein graft intimal hyperplasia,19 and
others have described cell proliferation and apoptosis after
vein graft interposition in a variety of models.16,17,20 The
end result of the vascular remodeling that follows vein graft
arterialization is intimal hyperplasia, which ultimately leads
to stenosis and reduced long-term graft patency. Although
the exact sequence of molecular events leading to intimal
hyperplasia has not been determined,1,6 many studies have
shown that the development of vein graft stenosis involves
migration and proliferation of smooth muscle cells into a
neointima with abundant deposition of extracellular matrix.2
A number of approaches have been used in attempts to
abolish or attenuate this medial response.21-23 However, the
elucidation of the mechanisms that regulate the response of
injured vessels is far from complete. To date, few studies
are available on the mechanisms of intimal hyperplasia and
the response to injury in vein grafts.20,24 However, the
intracellular signaling in response to vascular injury follow-
ing arterial balloon injury has been well characterized.6
Arterial injury results in rapid activation of ERK-1/2 and
JNK.6 However, the balloon injury model has a number of
limitations because it targets healthy vessels whereas clin-
ical interventions are performed on diseased ones. In addi-
tion, because the rat carotid artery has only rare intimal
cells,25 observations of the neointimal response to injury
may not translate to the human. Furthermore, leukocyte
infiltration is not observed in the rat model, unlike in human
vein grafts and large animal models.25 We found significant
leukocyte infiltration in canine vein grafts in the first few
hours after arterialization (Sharony et al, manuscript in
preparation, 2003).
The differences in MAPK activation between vein graft
arterialization and arterial balloon injury highlight the bio-
logical differences between these 2 mechanisms of injury.
Therefore, it is not surprising to observe different intracel-
lular responses in these 2 models. The vein graft has nu-
merous anatomic differences that alter its response to vas-
cular injury and limit its ability to adapt to arterial flow.5
A potential common feature of all vascular injuries is the
increased availability of growth factors and cytokines at the
site(s) of injury. These may originate from either circulating
cells, from cells within the vessel wall, or both.26 Addition-
ally, the existence of a cascade of growth factors27 affecting
vascular cells suggests a potential mechanism for the ob-
served bimodal MAPK response.6 Growth factor release
also points to a role for apoptosis in vascular remodeling.
Induction of apoptosis has been attempted to reduce intimal
hyperplasia by decreasing the actual number of medial cells
after arterial injury.28 However, cell death secondary to
arterial injury has been implicated in releasing growth fac-
tors that activate medial smooth muscle cells.29 This finding
points to a delicate balance of the cellular phenotypes in-
volved in vascular remodeling after injury. We showed that
release of fibroblast growth factor-2 is key to endothelial
cell repair through ERK-1/2 activation10,11 and that excision
and manipulation of saphenous veins being prepared for
grafting results in strong activation of growth factor-depen-
dent signaling pathways.15
Mechanical stretching associated with arterialization of
vein grafts has been shown to induce MAPK activation in
Figure 7. Vein-to-vein or artery-to-artery bypass does not induce
MAPK activation or PCNA expression. A, Representative Western
blot of ERK-1/2 and p38MAPK activation in arterialized vein bypass
grafts, vein-to-vein bypass grafts, and artery-to-artery bypass
grafts at 30 minutes following arterialization. B, Representative
Western blot of PCNA expression in arterialized vein bypass
grafts and vein-to-vein bypass grafts at 4 days following arteri-
alization. C, Control (contralateral external jugular vein, femoral
vein and femoral artery, respectively); AVG, arterialized vein
graft; V-VBG, vein-to-vein bypass graft; A-ABG, artery-to-artery
bypass graft.
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cultured smooth muscle cells17 and in excised human ves-
sels.18 Interestingly, Curi and colleagues18 have shown that
stretching can activate ERK-1/2 but not JNK, thus support-
ing the possibility that the observed differential activation of
MAPK pathways reported here may, at least in part, be due
to mechanical distention of the vein graft due to arterializa-
tion.
In light of the potential role played by MAPKs in vas-
cular remodeling, it is of interest that incubation of har-
vested saphenous vein grafts in a specific mitogen-activated
protein kinase kinase inhibitor effectively decreases ERK-
1/2 activation.15 These results prompt future investigations
aimed at interfering with MAPK pathways to probe their
involvement in vein graft medial proliferation and apoptosis
and, ultimately, in neointima formation.
Understanding the signaling pathways involved in arte-
rialization-induced vascular remodeling may complement
surgical intervention, leading to prevention of vein graft
intimal hyperplasia and, ultimately, restenosis and graft
failure. Harvested saphenous vein grafts are ideal targets for
molecular therapy as they are held in an isolated environ-
ment outside of the body prior to grafting.14 Specific syn-
thetic or gene-based inhibitors could be uniquely targeted at
vein grafts and achieve the desired control over the signal-
ing pathways without systemic effects.
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